EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association

Carmine Zoccali iD, Francesca Mallamaci, Marcin Adamczak, Rodrigo Bueno de Oliveira, Ziad A Massy, Pantelis Sarafidis iD, Rajiv Agarwal, Patrick B Mark, Peter Kotanko, Charles J Ferro, Christoph Wanner, Michel Burnier iD und 2 weitere

Cardiovascular Research · 05.09.2023 · 119 (11) · 2017-2032

DOI: 10.1093/cvr/cvad083 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 30.05.2023. Verfasst von Carmine Zoccali und 13 weiteren Autor:innen. Beteiligte Einrichtung: Renal Research Institute, 315 E, 62nd St., New York, NY 10065, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Cardiovascular Diseases, Heart Failure. Die Arbeit wurde bisher 382-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is classified into five stages with kidney failure being the most severe stage (stage G5). CKD conveys a high risk for coronary artery disease, heart failure, arrhythmias, and sudden cardiac death. Cardiovascular complications are the most common causes of death in patients with kidney failure (stage G5) who are maintained on regular dialysis treatment. Because of the high death rate attributable to cardiovascular (CV) disease, most patients with progressive CKD die before reaching kidney failure. Classical risk factors implicated in CV disease are involved in the early stages of CKD. In intermediate and late stages, non-traditional risk factors, including iso-osmotic and non-osmotic sodium retention, volume expansion, anaemia, inflammation, malnutrition, sympathetic overactivity, mineral bone disorders, accumulation of a class of endogenous compounds called ‘uremic toxins’, and a variety of hormonal disorders are the main factors that accelerate the progression of CV disease in these patients. Arterial disease in CKD patients is characterized by an almost unique propensity to calcification and vascular stiffness. Left ventricular hypertrophy, a major risk factor for heart failure, occurs early in CKD and reaches a prevalence of 70–80% in patients with kidney failure. Recent clinical trials have shown the potential benefits of hypoxia-inducible factor prolyl hydroxylase inhibitors, especially as an oral agent in CKD patients. Likewise, the value of proactively administered intravenous iron for safely treating anaemia in dialysis patients has been shown. Sodium/glucose cotransporter-2 inhibitors are now fully emerged as a class of drugs that substantially reduces the risk for CV complications in patients who are already being treated with adequate doses of inhibitors of the renin-angiotensin system. Concerted efforts are being made by major scientific societies to advance basic and clinical research on CV disease in patients with CKD, a research area that remains insufficiently explored.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicCardiovascular DiseasesHeart FailureHumansRenal DialysisSodium

Stichwörter der Autor:innen

Cardiovascular diseaseChronic kidney diseaseClinical aspectsDeathHeart failureSudden death

Substanzen

Sodium

Autor:innen und Institutionen

  • Renal Research Institute, 315 E, 62nd St., New York, NY 10065, USA.
  • Associazione Ipertensione Nefrologia e Trapianto Renale (IPNET) c/o Nefrologia e CNR, Grande Ospedale Metropolitano, Contrada Camporeale, 83031 Ariano Irpino Avellino, Italy.
  • Nephrology and Transplantation Unit, Grande Ospedale Metropolitano Reggio Cal and CNR-IFC, Via Giuseppe Melacrino 21, 89124 Reggio Calabria, Italy.
  • Department of Nephrology, Transplantation and Internal Medicine, Medical University of Silesia in Katowice, Francuska 20-24 St. 40-027 Katowice, Poland.
  • Department of Internal Medicine (Nephrology), School of Medical Sciences, University of Campinas (Unicamp), Campinas, Brazil.
  • Ambroise Paré University Hospital, APHP, Boulogne Billancourt/Paris, and INSERM U-1018, Centre de recherche en épidémiologie et santé des populations (CESP), Equipe 5, Paris-Saclay University (PSU) and University of Par…

ORCID-Profile: Carmine Zoccali, Pantelis Sarafidis, Michel Burnier, Raymond Vanholder

Zitieren

APA

Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., Wanner, C., Burnier, M., Vanholder, R., & Wiecek, A. (2023). Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovascular Research, 119(11), 2017-2032. https://doi.org/10.1093/cvr/cvad083

Vancouver

Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovascular Research. 2023;119(11):2017-2032. doi:10.1093/cvr/cvad083

BibTeX
@article{Zoccali2023,
  author = {Zoccali, Carmine and Mallamaci, Francesca and Adamczak, Marcin and de Oliveira, Rodrigo Bueno and Massy, Ziad A and Sarafidis, Pantelis and Agarwal, Rajiv and Mark, Patrick B and Kotanko, Peter and Ferro, Charles J and Wanner, Christoph and Burnier, Michel and Vanholder, Raymond and Wiecek, Andrzej},
  title = {Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association},
  journal = {Cardiovascular Research},
  year = {2023},
  volume = {119},
  number = {11},
  pages = {2017--2032},
  doi = {10.1093/cvr/cvad083}
}
Kostenlos starten →